Goldman Sachs Group Inc. decreased its position in shares of Antares Pharma, Inc. (NASDAQ:ATRS) by 34.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 379,642 shares of the specialty pharmaceutical company’s stock after selling 197,022 shares during the period. Goldman Sachs Group Inc. owned 0.24% of Antares Pharma worth $1,222,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Northern Trust Corp grew its stake in shares of Antares Pharma by 478.1% in the 2nd quarter. Northern Trust Corp now owns 1,654,266 shares of the specialty pharmaceutical company’s stock valued at $5,327,000 after purchasing an additional 1,368,131 shares during the last quarter. Rubric Capital Management LP grew its stake in shares of Antares Pharma by 34.4% in the 2nd quarter. Rubric Capital Management LP now owns 3,188,600 shares of the specialty pharmaceutical company’s stock valued at $10,267,000 after purchasing an additional 816,630 shares during the last quarter. Morgan Stanley grew its stake in shares of Antares Pharma by 153.3% in the 1st quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock valued at $2,829,000 after purchasing an additional 602,834 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Antares Pharma by 10.1% in the 2nd quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock valued at $19,920,000 after purchasing an additional 567,144 shares during the last quarter. Finally, TIAA CREF Investment Management LLC purchased a new position in shares of Antares Pharma in the 2nd quarter valued at approximately $1,251,000. 36.84% of the stock is currently owned by institutional investors.
Shares of Antares Pharma, Inc. (ATRS) opened at $1.72 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34. Antares Pharma, Inc. has a 12 month low of $1.58 and a 12 month high of $4.09.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The firm had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.01 million. Antares Pharma’s revenue for the quarter was up 11.9% on a year-over-year basis. equities analysts predict that Antares Pharma, Inc. will post -0.11 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.truebluetribune.com/2017/11/14/antares-pharma-inc-atrs-shares-sold-by-goldman-sachs-group-inc.html.
Several research analysts have weighed in on the company. Piper Jaffray Companies set a $3.00 target price on Antares Pharma and gave the company a “buy” rating in a research note on Monday, October 23rd. HC Wainwright set a $5.00 target price on Antares Pharma and gave the company a “buy” rating in a research note on Wednesday, August 9th. Vetr upgraded Antares Pharma from a “hold” rating to a “buy” rating and set a $3.42 target price on the stock in a research note on Tuesday, July 18th. Finally, ValuEngine downgraded Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $3.84.
In related news, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leonard S. Jacob sold 230,000 shares of Antares Pharma stock in a transaction on Monday, October 9th. The stock was sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is owned by insiders.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.